Drugs in Dev. Ophthalmology
Phase II
China 
Lead Product(s) : Efdamrofusp Alfa
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent Doses First Patient in Phase 2 Study of IBI302 for Macular Edema
Details : IBI302 (efdamrofusp alfa) is a first-in-class anti-VEGF and anti-complement bispecific fusion protein, which is currently being evaluated for the treatment of diabetic macular edema.
Product Name : IBI302
Product Type : Protein
Upfront Cash : Inapplicable
May 06, 2025
Lead Product(s) : Efdamrofusp Alfa
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efdamrofusp Alpha
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aileron Announces Pricing of Underwritten Registered Direct Offering of Up to $40 Million
Details : IBI302 (efdamrofusp alfa) is a recombinant human VEGFR-Fc-Human CR1 fusion protein injection. It is being evaluated for the treatment of patients with neovascular age-related macular degeneration.
Product Name : IBI302
Product Type : Antibody
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : Efdamrofusp Alpha
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VVN539
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VVN539 Met Primary Study Endpoints in US Phase IIa Clinical Study for The Treatment of Glaucoma
Details : VVN539 Ophthalmic Solution is a first-in-class small molecule for the treatment of glaucoma. It acts directly at trabecular meshwork, increases the outflow of aqueous humor for the treatment of with primary open angle glaucoma.
Product Name : VVN539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2023
Lead Product(s) : VVN539
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Foselutoclax
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Unity Biotechnology
Deal Size : $2.0 million
Deal Type : Licensing Agreement
Details : UBX1325 is a small-molecule inhibitor of Bcl-xL, and the first senolytic therapeutic clinically evaluated in an ophthalmological setting. UBX1325 is developed from BM-962, a drug candidate licensed to UNITY by Ascentage Pharma.
Product Name : UBX1325
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 28, 2021
Lead Product(s) : Foselutoclax
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Unity Biotechnology
Deal Size : $2.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Efdamrofusp Alpha
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBI302 has ability to inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation. The primary objective of the study is to evaluate the efficacy and safety of IBI302 in the treatmen...
Product Name : IBI302
Product Type : Antibody
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Efdamrofusp Alpha
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
